Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
| العنوان: | Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France |
|---|---|
| المؤلفون: | Rémi Monnier, B Tehard, Stéphane Roze, Marine Sivignon |
| المصدر: | PLoS ONE PLoS ONE, Vol 15, Iss 1, p e0226196 (2020) |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Alectinib, Oncology, Male, Lung Neoplasms, Cost effectiveness, Economics, Cost-Benefit Analysis, Cancer Treatment, Extrapolation, Social Sciences, Lung and Intrathoracic Tumors, Geographical locations, 0302 clinical medicine, Piperidines, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Anaplastic Lymphoma Kinase, 030212 general & internal medicine, Neurological Tumors, Randomized Controlled Trials as Topic, Numerical Analysis, Multidisciplinary, Middle Aged, Prognosis, Survival Rate, Europe, Neurology, Research Design, 030220 oncology & carcinogenesis, Physical Sciences, Medicine, Female, France, Quality-Adjusted Life Years, medicine.drug, Research Article, medicine.medical_specialty, Clinical Research Design, Science, Cost-Effectiveness Analysis, Carbazoles, Context (language use), Research and Analysis Methods, 03 medical and health sciences, Crizotinib, Internal medicine, medicine, Humans, European Union, Survival rate, Survival analysis, Models, Statistical, business.industry, Cancers and Neoplasms, Economic Analysis, Quality-adjusted life year, Non-Small Cell Lung Cancer, Clinical trial, Clinical Trials, Phase III as Topic, Brain Metastasis, Adverse Events, People and places, business, Mathematics, Follow-Up Studies |
| الوصف: | The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting. This study used a partitioned survival model, with three discrete health states (progression-free survival, post-progression survival and death). Survival probabilities were derived from a randomised Phase III clinical trial comparing alectinib to crizotinib (ALEX). Beyond the length of the trial (18 months), the efficacy of both treatments was considered equivalent. Occurrence of adverse events or brain metastases were considered as inter-current events. Utilities (and disutilities for intercurrent adverse events) derived from the EQ-5D were applied. Costs were attributed using standard French national public health tariffs. Projected mean overall survival was 4.62 years for alectinib and 4.18 years for crizotinib. Projected mean progression-free survival was 30.30 months for alectinib and 16.13 months for crizotinib. The total number of quality-adjusted life years projected was 3.40 for alectinib and 2.84 for crizotinib. The projected total cost of treatment over the lifetime of the model was € 246,022 for alectinib and € 195,486 for crizotinib. This extra cost was principally attributable to treatment acquisition costs and management before progression. Alectinib was associated with lower costs related to brain metastases and to management post-progression. The incremental cost per life year gained was 115,334 €/year and the incremental cost-effectiveness ratio was 90,232 €/QALY. First-line treatment of ALK+ NSCLC with alectinib provides superior clinical outcomes to crizotinib and is cost-effective in the French context. |
| تدمد: | 1932-6203 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1dd95c7d483bff64b6b4ac3349da175 https://pubmed.ncbi.nlm.nih.gov/31945065 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....c1dd95c7d483bff64b6b4ac3349da175 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|